Straumann Holding AG

Straumann is engaged in tooth replacement solutions that include dental implants, prosthetics and regenerative products. Co. develops, manufactures and supplies dental implants, instruments, computer-aided design/computer-aided manufacturing prosthetics and tissue regeneration products for use in tooth replacement and restoration solutions or to prevent tooth loss. Co. provides a range of services to dental practitioners, clinics and laboratories. Through a collaboration with its academic partner the International Team for Implantology ( ITI), Co. supports research and offers training and education to dental professionals worldwide.
  • TickerSTMN
  • ISINCH0012280076
  • ExchangeSix Swiss Exchange
  • SectorHealth Care Equipment & Services
  • CountrySwitzerland

Analysts

Straumann Holding Ag: 1 director sold

A director at Straumann Holding Ag sold 150 shares at 900.000CHF and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of b...

STRAUMANN HOLDING AG sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of STRAUMANN HOLDING AG (CH), a company active in the Medical Equipment industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date October 11, 2019, the closing price was CHF 844.40 and its potential was estimated at CHF 905.92.

MarketLine Department

Zimmer Biomet Holdings Inc. - Strategy, SWOT and Corporate Finance Report

Summary Zimmer Biomet Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. KeyHighlights Zimmer Biomet Holdings Inc. (Zimmer Biomet or ‘the company’) is a designer, manufacturer and marketer of medical devices. The company offers sports medicine, orthopaedic reconstructive products, extremities, spine, biologics and trauma products, craniomaxillofacial and thoracic pr...

Damien Conover

Morningstar | Straumann's 1Q Performance Broadly Met Our Expectations Amid Healthy Organic Growth

Straumann's fiscal first-quarter earnings results showed strength across its core businesses and broadly met our expectations. The company reiterated its 2019 outlook, and we do not anticipate major changes to our fair value estimate or our narrow moat rating. Despite a degree of seasonal digital hardware softness, the company still posted double-digit organic revenue growth across all regions. Straumann posted healthy growth across all regions during the period, mainly thanks to its implant business. We think the premium and nonpremium implant businesses should continue to fuel the company's...

Damien Conover

Morningstar | Straumann's 1Q Performance Broadly Met Our Expectations Amid Healthy Organic Growth. See Updated Analyst Note from 30 Apr 2019

Straumann's fiscal first-quarter earnings results showed strength across its core businesses and broadly met our expectations. The company reiterated its 2019 outlook, and we do not anticipate major changes to our fair value estimate or our narrow moat rating. Despite a degree of seasonal digital hardware softness, the company still posted double-digit organic revenue growth across all regions. Straumann posted healthy growth across all regions during the period, mainly thanks to its implant business. We think the premium and nonpremium implant businesses should continue to fuel the company's...

Damien Conover

Morningstar | Straumann's 1Q Performance Broadly Met Our Expectations Amid Healthy Organic Growth

Straumann's fiscal first-quarter earnings results showed strength across its core businesses and broadly met our expectations. The company reiterated its 2019 outlook, and we do not anticipate major changes to our fair value estimate or our narrow moat rating. Despite a degree of seasonal digital hardware softness, the company still posted double-digit organic revenue growth across all regions. Straumann posted healthy growth across all regions during the period, mainly thanks to its implant business. We think the premium and nonpremium implant businesses should continue to fuel the company's...

Damien Conover

Morningstar | Straumann's 1Q Performance Broadly Met Our Expectations Amid Healthy Organic Growth. See Updated Analyst Note from 30 Apr 2019

Straumann's fiscal first-quarter earnings results showed strength across its core businesses and broadly met our expectations. The company reiterated its 2019 outlook, and we do not anticipate major changes to our fair value estimate or our narrow moat rating. Despite a degree of seasonal digital hardware softness, the company still posted double-digit organic revenue growth across all regions. Straumann posted healthy growth across all regions during the period, mainly thanks to its implant business. We think the premium and nonpremium implant businesses should continue to fuel the company's...

Damien Conover

Straumann's 1Q Performance Broadly Met Our Expectations Amid Healthy Organic Growth

Straumann's fiscal first-quarter earnings results showed strength across its core businesses and broadly met our expectations. The company reiterated its 2019 outlook, and we do not anticipate major changes to our fair value estimate or our narrow moat rating. Despite a degree of seasonal digital hardware softness, the company still posted double-digit organic revenue growth across all regions. Straumann posted healthy growth across all regions during the period, mainly thanks to its implant bus...

Damien Conover

Morningstar | STMN Updated Forecasts and Estimates from 05 Apr 2019

Straumann has made a name for itself as a global leader in the dental implant industry, consistently gaining market share from competitors through product launches, strategic acquisitions, and operational expansion. The implant market, which provides patients with a cost-effective option for single-tooth replacement, remains one of the more attractive segments of the dental industry, in our view. This market typically grows slightly faster than global GDP, thanks to increasing oral health awareness, low reimbursement risk, and an aging population. Furthermore, Straumann’s implant volume benefi...

Damien Conover

Morningstar | Straumann Facing Strong Dental Market Headwinds

Straumann has made a name for itself as a global leader in the dental implant industry, consistently gaining market share from competitors through product launches, strategic acquisitions, and operational expansion. The implant market, which provides patients with a cost-effective option for single-tooth replacement, remains one of the more attractive segments of the dental industry, in our view. This market typically grows slightly faster than global GDP, thanks to increasing oral health awareness, low reimbursement risk, and an aging population. Furthermore, Straumann’s implant volume benefi...

Straumann Holding Ag: 1 director sold

A director at Straumann Holding Ag sold 150 shares at 900.000CHF and the significance rating of the trade was 59/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of b...

STRAUMANN HOLDING AG sees an upgrade to Slightly Positive due to a better fundamental star rating

The general evaluation of STRAUMANN HOLDING AG (CH), a company active in the Medical Equipment industry, has been upgraded by the independent financial analyst theScreener with the addition of a star. Its fundamental valuation now shows 4 out of 4 possible stars while its market behaviour can be considered as moderately risky. theScreener believes that the additional star(s) merits the upgrade of its general evaluation to Slightly Positive. As of the analysis date October 11, 2019, the closing price was CHF 844.40 and its potential was estimated at CHF 905.92.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the week...

MarketLine Department

Zimmer Biomet Holdings Inc. - Strategy, SWOT and Corporate Finance Report

Summary Zimmer Biomet Holdings Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. KeyHighlights Zimmer Biomet Holdings Inc. (Zimmer Biomet or ‘the company’) is a designer, manufacturer and marketer of medical devices. The company offers sports medicine, orthopaedic reconstructive products, extremities, spine, biologics and trauma products, craniomaxillofacial and thoracic pr...

Straumann Holding – Proxinvest Corporate Governance Rating ® : B

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

Health Care outperforming globally -- overweight; India breaking out -- add exposure With the primary global ex-U.S. indexes MSCI EAFE, MSCI EM, and MSCI ACWI ex-U.S. continuing their sideways to downward consolidation from a price perspective, the importance of Sector, Group, and stock selection is critical. • Sector and Group Opportunities. Today we put the spotlight on the Health Care Sector, which is assuming a global leadership role as it separates itself from the other international Sectors. We also focus on the Communications Sector as it has seen steady relative strength ranking (RSR...

Dave Nicoski ...
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

The U.S. has continued to separate itself from broad emerging market and developed international indexes. Thankfully, one positive is that MSCI EM and MSCI EAFE have been able to stabilize from a price perspective despite relative strength weakness vs. MSCI ACWI... see charts below. In today's report we scour the globe for attractive investments in an environment where selectivity is key. • Emerging markets. There is still not much to like about broad EM as the MSCI Emerging Markets index has remained weak following price and relative strength breakdowns. Remain underweight broad EM and be...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch